- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04784780
Long-term Elobixibat for Chronic Constipation (TANK-27)
Long-term Efficacy and Safety of Elobixibat for Chronic Constipation: a Multicenter, Randomised, Double-blind, Placebo-controlled Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Takaomi Kessoku, M.D., PhD.
- Phone Number: 2640 +81-45-787-2800
- Email: kessoku-tho@umin.ac.jp
Study Contact Backup
- Name: Atsushi Nakajima, M.D., PhD.
- Phone Number: 2640 +81-45-787-2800
- Email: nakajima-tky@umin.ac.jp
Study Locations
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 236-0004
- Recruiting
- Yokohama City University
-
Contact:
- Takaomi Kessoku, MD., PhD.
- Phone Number: 2640 +81-45-787-2800
- Email: kessoku-tho@umin.ac.jp
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with chronic constipation by the "Rome IV" criteria for chronic constipation
- Age: 20 years old or older and up to 85 years old (at the time of obtaining consent)
- Gender: any gender
- outpatients
- Patients who can obtain written consent
- Patients who can record their defecation, etc. in the patient's diary
At the time of allocation (dosing initiation criteria)
- Spontaneous bowel movements (SBM)* not more than 6 times during the 2-week observation period before the start of treatment
- Patients with no soft or watery stools (Bristol Stool Shape Scale 6 or 7) in spontaneous bowel movements during the 2-week observation period before the start of treatment.
- Patients who have not used concomitantly prohibited drugs or therapies during the observation period.
Exclusion Criteria:
- Patients with organic constipation or patients with suspected organic constipation.
- Patients with or suspected of having functional ileus.
- Patients with or suspected of having an inguinal hernia.
- Patients with a history of open surgery within 12 weeks before obtaining consent (excluding appendicitis resection).
- Patients with a history of surgical or endoscopic procedures related to cholecystectomy and papillotomy.
- Patients with complications of malignancy.
- Pregnant women, lactating women, women who may be currently pregnant, or patients who cannot consent to use contraception while participating in the study.
- Patients with serious renal, liver, or cardiac disease.
- Patients who are allergic to this study drug.
- Patients who have previously taken Goufis tablets (elobixibat).
- Patients with contraindications to rescue drugs (bisacodyl suppositories and prusenide tablets).
- Patients who are participating in another clinical study or who were participating in another clinical study within 4 weeks before consent was obtained, excluding observational studies.
- Patients who are judged by the principal investigator or sub-physician to be inappropriate for conducting this research.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Elobixibat
AJG533 (elobixibat) 10 mg orally once a day before meals for 12 weeks
|
Patients with chronic constipation are administered Elobixibat 10mg for 12 weeks
Other Names:
|
Placebo Comparator: Placebo
AJG533 placebo orally once a day before meals for 12 weeks
|
Patients with chronic constipation are administered placebo for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the number of complete spontaneous bowel movements at week 12
Time Frame: Week 12
|
Change in the number of complete spontaneous bowel movements at week 12 of the treatment period from week 2 of the observation period.
*Spontaneous defecation without residual sensation.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the number of complete spontaneous bowel movements in each week of the treatment period.
Time Frame: Each Week 1-11
|
Change in the number of complete spontaneous bowel movements in each week of the treatment period.
|
Each Week 1-11
|
Change in the number of spontaneous bowel movements in each week of the treatment.
Time Frame: Each Week 1-11
|
Change in the number of spontaneous bowel movements in each week of the treatment.
|
Each Week 1-11
|
Proportion of responders** in the number of SBMs during each week.
Time Frame: Each Week 1-11
|
Proportion of responders** in the number of spontaneous bowel movements (SBMs) during each week of the treatment period. **In this study, we will investigate the effect of the treatment on the number of SBMs of a subject who has at least one more SBM per week than in the second week of the observation period, and at least three times per week. |
Each Week 1-11
|
Proportion of responders** in the number of CSBMs during each week.
Time Frame: Each Week 1-11
|
Proportion of responders** in the number of complete spontaneous a bowel movements (CSBMs) during each week of the treatment period. **In this study, we will investigate the effect of the treatment on the number of CSBMs of a subject who has at least one more CSBMs per week than in the second week of the observation period, and at least three times per week. |
Each Week 1-11
|
The rate of a responder in the number of CSBM during the treatment period.
Time Frame: Week 12
|
Definition of Responder: Patients with 3 or more CSBM per week and 1 or more CSBM per week from baseline for 9 weeks out of the entire treatment period (12 weeks), including at least 3 weeks in the treatment period weeks 9 to 12.
|
Week 12
|
Percent change in fecal hardness based on the Bristol Stool Quality Scale at each week.
Time Frame: Each Week 1-11
|
Percent change in fecal hardness from week 2 of the observation period based on the Bristol Stool Quality Scale at each week of the treatment period.
the minimum is 1 and maximum values, is 7.Higher scores mean a better outcome.
|
Each Week 1-11
|
The percentage of change in the presence or absence of residual sensation at each week.
Time Frame: Each Week 1-11
|
The percentage of change from week 2 of the observation period in the presence or absence of residual sensation at each week of the treatment period.
|
Each Week 1-11
|
Percent change in the degree of twitching at each week.
Time Frame: Each Week 1-11
|
Percent change from week 2 of the observation period in the degree of twitching at each week of the treatment period.
|
Each Week 1-11
|
The percentage of change in the presence or absence of bowel movements at each week.
Time Frame: Each Week 1-11
|
The percentage of change in the presence or absence of bowel movements at each week of the treatment period from week 2 of the observation period.
|
Each Week 1-11
|
Change in Japanese Patient assessment of constipation quality of life score
Time Frame: Week 4, 12
|
Change in Japanese Patient assessment of constipation quality of life score at 4 and 12 weeks of the treatment period from the baseline (V2) of the study drug.the
minimum is 0 and maximum values is 4.Lower scores mean a better outcome.
|
Week 4, 12
|
The changes in occupancy rate of intestinal microbiota.
Time Frame: Week 4, 12
|
At 4 weeks and 12 weeks of the treatment period, the changes in occupancy rate of intestinal microbiota in feces from before the start of the study drug (V2) are examined.
|
Week 4, 12
|
The change in absolute values rates in blood and fecal bile acids.
Time Frame: Week 4, 12
|
At 4 weeks and 12 weeks of the treatment period, the change in absolute values in blood and fecal bile acids from before the start of the study drug (V2) are examined.
|
Week 4, 12
|
The change in absolute values for organic acids.
Time Frame: Week 4, 12
|
At 4 weeks and 12 weeks of the treatment period, the change in absolute values for organic acids in feces from before the start of the study drug (V2) are examined.
|
Week 4, 12
|
The change in absolute values of amino acids in blood and feces.
Time Frame: Week 4, 12
|
At 4 weeks and 12 weeks of the treatment period, the change in absolute values of amino acids in blood and feces.
from before the start of the study drug (V2) are examined.
|
Week 4, 12
|
The change in amount blood C4.
Time Frame: Week 4, 12
|
At 4 weeks and 12 weeks of the treatment period, the change in amount blood C4 from before the start of the study drug (V2) are examined.
|
Week 4, 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events.
Time Frame: Each Week 1-11
|
Incidence of adverse events.
|
Each Week 1-11
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Takaomi Kessoku, M.D., PhD., Yokohama City University
Publications and helpful links
General Publications
- Nakajima A, Seki M, Taniguchi S, Ohta A, Gillberg PG, Mattsson JP, Camilleri M. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018 Aug;3(8):537-547. doi: 10.1016/S2468-1253(18)30123-7. Epub 2018 May 25.
- Tanaka K, Kessoku T, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Kobayashi T, Yoshihara T, Misawa N, Kato T, Arimoto J, Fuyuki A, Sakai E, Higurashi T, Chiba H, Hosono K, Yoneda M, Iwasaki T, Kurihashi T, Nakatogawa M, Suzuki A, Taguri M, Oyamada S, Ariyoshi K, Kobayashi N, Ichikawa Y, Nakajima A. Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation. BMJ Open. 2022 May 30;12(5):e060704. doi: 10.1136/bmjopen-2021-060704.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- jRCTs031200363
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
Air Force Military Medical University, ChinaRecruitingChronic ConstipationChina
-
Yokohama City UniversityRecruiting
-
TakedaThe Organization of Teratology Information SpecialistsRecruiting
-
TakedaUC San Diego Human Milk Research BiorepositoryRecruiting
-
International University of Health and WelfareTerminated
-
Astellas Pharma IncCompleted
Clinical Trials on Elobixibat 10mg
-
Yokohama City UniversityRecruiting
-
International University of Health and WelfareTerminated
-
Yokohama City UniversityEA Pharma Co., Ltd.CompletedNonalcoholic Steatohepatitis | Nonalcoholic Fatty LiverJapan
-
Ferring PharmaceuticalsTerminatedChronic Idiopathic ConstipationIsrael, Belgium, United States, United Kingdom, Germany, Poland, Brazil, Canada, Czech Republic, South Africa
-
Ferring PharmaceuticalsTerminatedChronic Idiopathic ConstipationSweden, Canada, Hungary, United States, Brazil, South Africa, Czech Republic, Germany, Mexico, Poland, Slovakia, United Kingdom
-
Ferring PharmaceuticalsCompletedChronic Idiopathic ConstipationUnited States, Belgium, Canada, Czech Republic, Hungary, Poland, Slovakia, South Africa, Sweden, United Kingdom
-
Ferring PharmaceuticalsWithdrawn
-
Michael Camilleri, MDNational Center for Research Resources (NCRR)CompletedFunctional ConstipationUnited States
-
AlbireoCompleted
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of